Master Pharmaceuticals Group: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.master-pharmaceuticals.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “The following claims concerning compounded semaglutide and tirzepatide products appear on your website:”

2. 2

   ““Semaglutide (Ozempic/Wegovy)””

3. 3

   ““Tirzepatide (Mounjaro/Zepbound)””

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

master-pharmaceuticals.com resolved on 2026-08-09 but served no storefront on either the apex or www host. Both returned a 4.7KB page titled "Redirecting..." containing only an ad-overlay detection script and a single obfuscated link; following that link returned a 140-byte page whose entire body is a script calling window.history.back(). No product page, no catalogue and no checkout was reachable. That is consistent with a domain no longer serving a business, but it is not proof of closure — a redirect layer can be removed and a company can trade elsewhere. Recorded as unknown rather than ceased-operations.

This is the page that says the least, and it is worth knowing that saying less did not help. There is no argument to disagree with: a name, a bracket, two brands, a slash. And that is exactly why FDA read it as a claim of sameness — a bracket after a product name is, by convention, an explanation of what the product IS, the same convention that makes "paracetamol (Tylenol)" useful at a pharmacy counter. The convention is doing the persuading, silently, which is what makes it hard to notice and impossible to fact-check. So the reader's rule cannot be "look for overstated claims", because there is nothing here to overstate; it has to be a question asked of every listing that carries a brand in brackets — is this product the one in the bracket, or is it something else being explained by reference to it? A second, blunter signal is worth naming too: FDA had no street address, no company officer and no legal entity to write to. Everything the agency could establish about who was selling this came from an email address. When that is all a regulator can find, it is also all a customer would have found. Nothing here is a finding about quality, contents or manufacturing, and the letter has not been closed out.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Master Pharmaceuticals Group failed to respond.